Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3open accessMajor clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
- Other Titles
- Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
- Authors
- Lee, Jung-Yun; Lee, Yoo-Young; Park, Jeong-Yeol; Shim, Seung-Hyuk; Kim, Se Ik; Kong, Tae-Wook; Lim, Chul Kwon; Cho, Hyun Woong; Suh, Dong Hoon
- Issue Date
- Mar-2023
- Publisher
- 대한부인종양학회
- Keywords
- Overall Survival; Immunotherapy; Molecular Targeted Therapy; Poly(ADP-Ribose) Polymerase Inhibitor; Hyperthermic Intraperitoneal Chemotherapy
- Citation
- Journal of Gynecologic Oncology, v.34, no.2, pp 1 - 26
- Pages
- 26
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Journal of Gynecologic Oncology
- Volume
- 34
- Number
- 2
- Start Page
- 1
- End Page
- 26
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62767
- DOI
- 10.3802/jgo.2023.34.e51
- ISSN
- 2005-0380
2005-0399
- Abstract
- In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Obstetrics and Gynecology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.